{
  "id": [
    "32576276"
  ],
  "source": [
    "MED"
  ],
  "pmid": [
    "32576276"
  ],
  "pmcid": [
    "PMC7309195"
  ],
  "fullTextIdList": [
    {
      "fullTextId": [
        "PMC7309195"
      ]
    }
  ],
  "doi": [
    "10.1186/s12967-020-02427-4"
  ],
  "title": [
    "\"Right-to-Try\" experimental drugs: an overview."
  ],
  "authorString": [
    "Mahant V."
  ],
  "authorList": [
    {
      "author": [
        {
          "fullName": [
            "Mahant V"
          ],
          "firstName": [
            "Vijay"
          ],
          "lastName": [
            "Mahant"
          ],
          "initials": [
            "V"
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "MediLite Diagnostika, Inc, 12364 Carmel Country Rd, San Diego, CA, 92130, USA. vijaymedilite@msn.com."
              ]
            }
          ]
        }
      ]
    }
  ],
  "dataLinksTagsList": [
    {
      "dataLinkstag": [
        "altmetrics"
      ]
    }
  ],
  "journalInfo": [
    {
      "issue": [
        "1"
      ],
      "volume": [
        "18"
      ],
      "journalIssueId": [
        "2962442"
      ],
      "dateOfPublication": [
        "2020 Jun"
      ],
      "monthOfPublication": [
        "6"
      ],
      "yearOfPublication": [
        "2020"
      ],
      "printPublicationDate": [
        "2020-06-01"
      ],
      "journal": [
        {
          "title": [
            "Journal of translational medicine"
          ],
          "ISOAbbreviation": [
            "J Transl Med"
          ],
          "medlineAbbreviation": [
            "J Transl Med"
          ],
          "NLMid": [
            "101190741"
          ],
          "ISSN": [
            "1479-5876"
          ],
          "ESSN": [
            "1479-5876"
          ]
        }
      ]
    }
  ],
  "pubYear": [
    "2020"
  ],
  "pageInfo": [
    "253"
  ],
  "abstractText": [
    "The \"Right-to-Try\" experimental drugs act passed by Donald Trump in 2018 provides an opportunity of early access to experimental drugs for the treatment of life-threatening diseases and a potential boon to many young and under-capitalized biotechnology or pharmaceutical companies. The pros and cons of experimental drugs, including a number of \"cutting edge\" scientific, clinical, and a number of synergistic approaches such as artificial intelligence, machine learning, big data, data refineries, electronic health records, data driven clinical decisions and risk mitigation are reviewed."
  ],
  "affiliation": [
    "MediLite Diagnostika, Inc, 12364 Carmel Country Rd, San Diego, CA, 92130, USA. vijaymedilite@msn.com."
  ],
  "publicationStatus": [
    "epublish"
  ],
  "language": [
    "eng"
  ],
  "pubModel": [
    "Electronic"
  ],
  "pubTypeList": [
    {
      "pubType": [
        "review-article",
        "Review",
        "Journal Article"
      ]
    }
  ],
  "keywordList": [
    {
      "keyword": [
        "Artificial intelligence",
        "Machine Learning",
        "Ehr",
        "Precision Medicine",
        "Rwd",
        "Panomics",
        "Rwe",
        "Catrip And Cabig",
        "“Right-to-try” Experimental Drugs"
      ]
    }
  ],
  "subsetList": [
    {
      "subset": [
        {
          "code": [
            "IM"
          ],
          "name": [
            "Index Medicus"
          ]
        }
      ]
    }
  ],
  "fullTextUrlList": [
    {
      "fullTextUrl": [
        {
          "availability": [
            "Subscription required"
          ],
          "availabilityCode": [
            "S"
          ],
          "documentStyle": [
            "doi"
          ],
          "site": [
            "DOI"
          ],
          "url": [
            "https://doi.org/10.1186/s12967-020-02427-4"
          ]
        },
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "html"
          ],
          "site": [
            "Europe_PMC"
          ],
          "url": [
            "https://europepmc.org/articles/PMC7309195"
          ]
        },
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "pdf"
          ],
          "site": [
            "Europe_PMC"
          ],
          "url": [
            "https://europepmc.org/articles/PMC7309195?pdf=render"
          ]
        }
      ]
    }
  ],
  "isOpenAccess": [
    "Y"
  ],
  "inEPMC": [
    "Y"
  ],
  "inPMC": [
    "N"
  ],
  "hasPDF": [
    "Y"
  ],
  "hasBook": [
    "N"
  ],
  "hasSuppl": [
    "N"
  ],
  "citedByCount": [
    "0"
  ],
  "hasData": [
    "N"
  ],
  "hasReferences": [
    "Y"
  ],
  "hasTextMinedTerms": [
    "Y"
  ],
  "hasDbCrossReferences": [
    "N"
  ],
  "hasLabsLinks": [
    "Y"
  ],
  "license": [
    "cc by"
  ],
  "authMan": [
    "N"
  ],
  "epmcAuthMan": [
    "N"
  ],
  "nihAuthMan": [
    "N"
  ],
  "hasTMAccessionNumbers": [
    "N"
  ],
  "dateOfCreation": [
    "2020-06-25"
  ],
  "firstIndexDate": [
    "2020-06-24"
  ],
  "fullTextReceivedDate": [
    "2020-07-09"
  ],
  "dateOfRevision": [
    "2020-09-03"
  ],
  "electronicPublicationDate": [
    "2020-06-23"
  ],
  "firstPublicationDate": [
    "2020-06-23"
  ]
}